当前位置： SCI文献检索 > CANCER CHEMOTHERAPY AND PHARMACOLOGY期刊下所有文献 > Effects of elotuzumab on QT interval and cardiac safety in patients with multiple myeloma.

Effects of elotuzumab on QT interval and cardiac safety in patients with multiple myeloma.

Abstract：

PURPOSE:To assess the effect of elotuzumab on corrected QT (QTc) intervals and cardiac safety. METHODS:Patients with high-risk smoldering multiple myeloma who had been treated with elotuzumab monotherapy (10 or 20 mg/kg) in Study CA204011 (NCT01441973) underwent electrocardiogram (ECG) examination over 8-10 weeks (treatment cycles 1-3). ECG intervals and changes relative to baseline were assessed. The key ECG endpoint was change from baseline in QT interval corrected with Fridericia's method (ΔQTcF). The relationship between elotuzumab concentration and ΔQTcF was assessed using time-matched ΔQTcF data and linear regression. Adverse events (AEs) potentially related to abnormal ECG findings were summarized. RESULTS:There was no trend of change from baseline in QTcF, PR and QRS intervals among all 31 evaluable patients from Study CA204011, and no patient assessed had a QTcF interval >480 ms or a ΔQTcF >60 ms. Concentration-response modeling indicated that there was no significant relationship between ΔQTcF and elotuzumab serum concentration: Upper limits of 90% confidence intervals for mean change in QTcF were <10 ms over the range of observed elotuzumab concentrations. No ECG-assessed patient had an AE associated with abnormal ECG findings potentially related to proarrhythmia. CONCLUSIONS:Study CA204011 ECG data indicate that elotuzumab treatment was not associated with QT/QTc prolongation. Concentration-response modeling demonstrated that baseline-adjusted QTcF changes did not cross thresholds for clinical or regulatory concern.

journal_name

Cancer Chemother Pharmacol

journal_title

Cancer chemotherapy and pharmacology

authors

Passey C,Darbenzio R,Jou YM,Lynch M,Gupta M

doi

10.1007/s00280-016-3182-8

subject

Has Abstract

pub_date

2016-12-01 00:00:00

pages

1237-1244

issue

6

eissn

0344-5704

issn

1432-0843

pii

10.1007/s00280-016-3182-8

journal_volume

78

pub_type

杂志文章

相关文献

CANCER CHEMOTHERAPY AND PHARMACOLOGY文献大全
  • Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 microl) blood samples.

    abstract：PURPOSE:The present study aims to establish a method that provides fast, precise and reproducible pharmacokinetic (PK) parameters of antibody-calicheamicin conjugates. The method should discriminate between PK of the antibody moiety and PK of the conjugated calicheamicin (CM). METHODS:The conjugates gemtuzumab ozogami...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-007-0560-2

    authors： Boghaert ER,Khandke KM,Sridharan L,Dougher M,DiJoseph JF,Kunz A,Hamann PR,Moran J,Chaudhary I,Damle NK

    更新日期：2008-05-01 00:00:00

  • A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement.

    abstract：:Detailed pharmacokinetic analysis and subsequent evaluation of myelotoxicity were performed in 55 patients who had been randomized to 4 different doses of epirubicin (40, 60, 90 or 135 mg/m2 given i.v. every 3 weeks). A significantly positive correlation was demonstrated between the AUC and the myelotoxicity of epirub...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1007/BF00685824

    authors： Jakobsen P,Bastholt L,Dalmark M,Pfeiffer P,Petersen D,Gjedde SB,Sandberg E,Rose C,Nielsen OS,Mouridsen HT

    更新日期：1991-01-01 00:00:00

  • Sonodynamic therapy with photofrin II on AH130 solid tumor. Pharmacokinetics, tissue distribution and sonodynamic antitumoral efficacy of photofrin II.

    abstract：BACKGROUND:The pharmacokinetics and tissue distribution of photofrin II (PF) and its efficacy in sonodynamic therapy were studied in rats bearing AH130 solid tumors. MATERIALS AND METHODS:In order to find the optimum timing of the ultrasound exposure after administration of PF, the PF concentrations in plasma, skin, m...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-002-0523-6

    authors： Yumita N,Umemura S

    更新日期：2003-02-01 00:00:00

  • Cell cycle effects and cellular pharmacology of 5-aza-2'-deoxycytidine.

    abstract：:The cytotoxic action of 5-aza-2'-deoxycytidine (5-AZA-CdR) in synchronized cells and logarithmic- and plateau-phase cultures of EMT6 murine tumor cells was investigated. 5-AZA-CdR produced a greater cell kill of S phase cells than of cells in G1 phase. Cells in the logarithmic phase of growth were more sensitive to th...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00269027

    authors： Momparler RL,Samson J,Momparler LF,Rivard GE

    更新日期：1984-01-01 00:00:00

  • A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms.

    abstract：PURPOSE:To determine the maximum tolerated dose (MTD) of perifosine (NSC 639966), an alkylphospholipid modulator of signal transduction, using different oral loading and maintenance regimens in an effort to avoid gastrointestinal toxicity while seeking maximal sustained plasma concentrations. METHODS:Thirty-one patien...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-014-2569-7

    authors： Figg WD,Monga M,Headlee D,Shah A,Chau CH,Peer C,Messman R,Elsayed YA,Murgo AJ,Melillo G,Ryan QC,Kalnitskiy M,Senderowicz AM,Hollingshead M,Arbuck SG,Sausville EA

    更新日期：2014-11-01 00:00:00

  • UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer.

    abstract：PURPOSE:Differences in efficacy and toxicity between UDP-glucuronosyltransferase (UGT) 1A1*1/*1 and *1/*6 or *1/*28 genotypes remain unclear in Japanese patients. METHODS:Patients with advanced colorectal cancer who received irinotecan combined with 5-fluorouracil plus l-leucovorin (FOLFIRI) as first-line therapy were...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-010-1485-8

    authors： Sunakawa Y,Ichikawa W,Fujita K,Nagashima F,Ishida H,Yamashita K,Mizuno K,Miwa K,Kawara K,Akiyama Y,Araki K,Yamamoto W,Miya T,Narabayashi M,Ando Y,Hirose T,Saji S,Sasaki Y

    更新日期：2011-08-01 00:00:00

  • Disruption of CTLA-4 expression on peripheral blood CD8 + T cell enhances anti-tumor efficacy in bladder cancer.

    abstract：:Activation of programmed death-1 (PD-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) on T cells leads to T cell exhaustion and ultimately facilitates tumor progression. Recent success of using immune cell checkpoint inhibitors offers a great promise to treat various cancers, including bladder cancer. However, the exp...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-019-03800-x

    authors： Zhang W,Shi L,Zhao Z,Du P,Ye X,Li D,Cai Z,Han J,Cai J

    更新日期：2019-05-01 00:00:00

  • Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues.

    abstract：PURPOSE:Pharmacokinetic analyses estimate the mean concentration of drug within a given tissue as a function of time, but do not give information about the spatial distribution of drugs within that tissue. Here, we compare the time-dependent spatial distribution of three anticancer drugs within tumors, heart, kidney, l...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-013-2176-z

    authors： Patel KJ,Trédan O,Tannock IF

    更新日期：2013-07-01 00:00:00

  • The impact of high-dose methotrexate on intracellular 6-mercaptopurine disposition during interval therapy of childhood acute lymphoblastic leukemia.

    abstract：PURPOSE:Low-dose methotrexate (MTX) therapy is the cornerstone treatment of acute lymphoblastic leukemia (ALL) and may enhance the activation of 6-mercaptopurine (6-MP) to 6-thioguanine nucleotides (6-TGN). Yet, data have established that high-dose MTX (HDMTX) hampers the accumulation of 6-TGN in red blood cells (RBC) ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-009-1205-4

    authors： Adam de Beaumais T,Dervieux T,Fakhoury M,Medard Y,Azougagh S,Zhang D,Yakouben K,Jacqz-Aigrain E

    更新日期：2010-09-01 00:00:00

  • Studies on the mechanism of 3-deazaguanine cytotoxicity in L1210-sensitive and -resistant cell lines.

    abstract：:3-Deazaguanine (3-DG), a purine analogue, has unusual antitumor activity against experimental mammary tumor models and a number of other solid tumors. Others have shown that mutant CHO cells deficient in hypoxanthine guanine phosphoribosyl transferase (HGPRTase) or adenine phosphoribosyl transferase (APRTase) are resi...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00273409

    authors： Singh G,Luna MK,Ardalan B

    更新日期：1988-01-01 00:00:00

  • Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study.

    abstract：:The pharmacokinetics and metabolism of 4-demethoxydaunorubicin (idarubicin, IDA) were studied in 21 patients with advanced cancer after i.v. (12 mg/m2) and oral (30-35 mg/m2) treatment according to a balanced crossover design. Patients were divided into four groups: subjects who showed normal liver and kidney function...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章

    doi：10.1007/BF00686301

    authors： Camaggi CM,Strocchi E,Carisi P,Martoni A,Tononi A,Guaraldi M,Strolin-Benedetti M,Efthymiopoulos C,Pannuti F

    更新日期：1992-01-01 00:00:00

  • Neoadjuvant chemotherapy for epithelial ovarian cancer--role of apoptosis.

    abstract：BACKGROUND:Ovarian cancer is one of the most frequently fatal gynecological cancers because most cases are diagnosed at an advanced stage. Loss of growth control and a marked resistance to apoptosis are considered major mechanisms driving tumor progression. Little is known about the effect of various treatment regimens...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1007/s00280-004-0993-9

    authors： Dutta T,Sharma H,Kumar L,Dinda AK,Kumar S,Bhatla N,Singh N

    更新日期：2005-10-01 00:00:00

  • Dosing algorithm revisit for busulfan following IV infusion.

    abstract：PURPOSE:Busulfan (Bu) exposure is critical for efficacy and safety. Body weight (BW), or adjusted ideal body weight (AIBW)-based dosing (WBD) algorithm, has been used in hematopoietic stem cell transplantation (HSCT). A recently completed phase 2 study revealed that 33.6 % of the subjects were under-, or over-exposed, ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-014-2660-0

    authors： Wang Y,Kato K,Le Gallo C,Armstrong E,Rock E,Wang X

    更新日期：2015-03-01 00:00:00

  • Comparative studies of DNA cross-linking reactions following methylene dimethanesulphonate and its hydrolytic product, formaldehyde.

    abstract：:The technique of alkaline elution was employed to study the interactions of methylene dimethane sulphonate (MDMS) and formaldehyde (HCHO) with DNA from Yoshida lymphosarcoma cells treated with these agents. MDMS and HCHO produced a proteinase sensitive filter retention which indicated the presence of DNA-protein cross...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00296247

    authors： O'Connor PM,Fox BW

    更新日期：1987-01-01 00:00:00

  • Doxifluridine (5'-dFUrd) in patients with advanced colorectal carcinoma. A phase II study.

    abstract：:Infusion of 5'-dFUrd (2.0-3.0 g/m2 over 1 h on days 1-5 every 3rd week) resulted in one partial response in 21 patients with advanced and progressing colorectal cancer. No patient had received chemotherapy before the 5'-dFUrd trial. Hematological and gastrointestinal toxicity were generally mild. In 4 patients periphe...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00257528

    authors： Fosså SD,Dahl O,Hoel R,Heier M,Loeb M

    更新日期：1985-01-01 00:00:00

  • Pharmacokinetics and toxicology of sparsomycin in beagle dogs.

    abstract：:Sparsomycin is a cytotoxic drug exhibiting a broad spectrum of in vitro activity against murine tumors and many tumor cell lines. It also appears to be a potent stimulator of the antitumor activity of cisplatin against L1210 leukemia in vivo. However, because of its toxicity, the antitumor activity of sparsomycin on m...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00253964

    authors： Zylicz Z,Wagener DJ,Fernandez del Moral P,van Rennes H,Wessels JM,Winograd B,van der Kleijn E,Vree TB,van Haelst U,van den Broek LA

    更新日期：1987-01-01 00:00:00

  • Preclinical toxicology, pharmacokinetics and formulation of N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine (trimelamol), a water-soluble cytotoxic s-triazine which does not require metabolic activation.

    abstract：:N2,N4,N6-Trihydroxymethyl-N2,N4,N6-trimethylmelamine (Trimelamol) is a water-soluble synthetic s-triazine which, unlike hexamethylmelamine (HMM) and pentamethylmelamine (PMM), does not require metabolic activation. The physico-chemical characteristics of Trimelamol were studied with the aim of overcoming the problems ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00256694

    authors： Rutty CJ,Judson IR,Abel G,Goddard PM,Newell DR,Harrap KR

    更新日期：1986-01-01 00:00:00

  • Ineligibility for the PACIFIC trial in unresectable stage III non-small cell lung cancer patients.

    abstract：PURPOSE:Recently, based on results of the PACIFIC trial, durvalumab after chemoradiotherapy (CRT) became the standard therapy for unresectable stage III non-small cell lung cancer (NSCLC). However, in the PACIFIC trial, patients were recruited and randomized after CRT, and certain patients were considered ineligible af...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-019-03885-4

    authors： Hosoya K,Fujimoto D,Kawachi H,Sato Y,Kogo M,Nagata K,Nakagawa A,Tachikawa R,Hiraoka S,Kokubo M,Tomii K

    更新日期：2019-08-01 00:00:00

  • MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer.

    abstract：PURPOSE:The level of drug metabolism and drug transport is correlated with the sensitivity of cancer cells towards platinum-based chemotherapy. We hypothesize that genetic polymorphisms in metabolising enzymes gene GSTP1 (glutathione S-transferase P1), and MRP2 (multidrug resistance-associated protein 2) (ABCC2), which...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章

    doi：10.1007/s00280-009-1046-1

    authors： Sun N,Sun X,Chen B,Cheng H,Feng J,Cheng L,Lu Z

    更新日期：2010-02-01 00:00:00

  • A phase I trial of continuous-infusion cyclophosphamide in refractory cancer patients.

    abstract：:Cyclophosphamide demonstrates enhanced tumoricidal activity with decreased bone marrow toxicity when given on a divided-dose schedule in certain animal models. A total of 22 patients presenting with refractory metastatic cancer were treated in a phase I trial of continuous infusion of cyclophosphamide over 96 h. Granu...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00686337

    authors： Eder JP,Elias AD,Ayash L,Wheeler CA,Shea TC,Schnipper LE,Frei E 3rd,Antman KH

    更新日期：1991-01-01 00:00:00

  • Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer.

    abstract：BACKGROUND:This phase 1 study evaluated the safety, tolerability, pharmacokinetics and efficacy of patritumab (U3-1287) Process 2, a new formulation of fully human anti-HER3 monoclonal antibody in combination with erlotinib, an epidermal growth factor receptortyrosine kinase inhibitor (EGFR-TKI) in prior chemotherapy t...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-016-3231-3

    authors： Shimizu T,Yonesaka K,Hayashi H,Iwasa T,Haratani K,Yamada H,Ohwada S,Kamiyama E,Nakagawa K

    更新日期：2017-03-01 00:00:00

  • Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy.

    abstract：PURPOSE:Many patients with non-small cell lung cancer (NSCLC) are eligible only for palliative radiation (RT) at presentation. This study was designed to assess the feasibility of adding the anti-EGFR monoclonal antibody nimotuzumab to palliative thoracic RT. METHODS:Patients with stage IIB, III or IV NSCLC considered...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-010-1379-9

    authors： Bebb G,Smith C,Rorke S,Boland W,Nicacio L,Sukhoo R,Brade A

    更新日期：2011-04-01 00:00:00

  • Carbonate and carbamate derivatives of 4-demethylpenclomedine as novel anticancer agents.

    abstract：PURPOSE:The purpose of this investigation was to synthesize a series of carbonate and carbamate derivatives of 4-demethylpenclomedine (DM-PEN), the major plasma non-toxic metabolite of penclomedine (PEN) seen in patients. DM-PEN has been observed to be an active antitumor agent in mouse human xenograft tumor models and...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-009-0933-9

    authors： Morgan LR,Struck RF,Waud WR,LeBlanc B,Rodgers AH,Jursic BS

    更新日期：2009-09-01 00:00:00

  • Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens.

    abstract：PURPOSE:To assess the activity and safety of combined folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC) in metastatic breast cancer patients previously treated with at least two chemotherapy regimens. PATIENTS AND METHODS:A total of 104 consecutive patients were enrolled for treatment with FA 100 mg/m(2) ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章

    doi：10.1007/s00280-002-0495-6

    authors： Francini G,Petrioli R,Messinese S,Pozzessere D,Marsili S,Correale P,Sabatino M,Fiaschi AI

    更新日期：2002-10-01 00:00:00

  • Renal function in the elimination of oral melphalan in patients with multiple myeloma.

    abstract：:Pharmacokinetic studies in 11 patients with multiple myeloma were undertaken on the first and last days of one course of chemotherapy. The drug was administered PO in single doses of 6-14 mg daily. Melphalan concentrations were determined by high-performance liquid chromatography. The interpatient variability of pharm...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00306752

    authors： Adair CG,Bridges JM,Desai ZR

    更新日期：1986-01-01 00:00:00

  • Influence of tumor size on the main drug-metabolizing enzyme systems in mouse colon adenocarcinoma Co38.

    abstract：:Mouse colon adenocarcinoma Co38 is widely used as a screening model for human colon tumors. To understand better the influence of tumor size on the main drug-metabolizing enzyme systems, we tested 15 mouse Co38 tumors at different sizes. The average weight was 917 +/- 444 mg (range, 300-1,400 mg). Cytochromes P-450 (1...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00685661

    authors： Massaad L,Chabot GG,Toussaint C,Koscielny S,Morizet J,Bissery MC,Gouyette A

    更新日期：1994-01-01 00:00:00

  • Protein expression profiling identifies differential modulation of homologous recombination by platinum-based antitumor agents.

    abstract：PURPOSE:Oxaliplatin and satraplatin demonstrate activity against cisplatin-resistant tumor cells. Although the two platinum analogs are structurally-related, oxaliplatin is more active. Therefore, studies focusing on protein expression profiling were undertaken to identify the molecular mechanism for the difference in ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-020-04085-1

    authors： He G,Xie X,Siddik ZH

    更新日期：2020-06-01 00:00:00

  • Efficacy and safety of liposome-paclitaxel and carboplatin based concurrent chemoradiotherapy for locally advanced lung squamous cell carcinoma.

    abstract：OBJECTIVE:The aim of this study was to evaluate the efficacy and toxicities of liposome-paclitaxel and carboplatin concurrent with radiotherapy for locally advanced lung squamous cell carcinoma (LSCC). METHODS:The clinical data of 38 patients with locally advanced LSCC treated with liposome-paclitaxel based concurrent...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-018-3640-6

    authors： Chen G,Sheng L,Du X

    更新日期：2018-09-01 00:00:00

  • In vitro effect of liposome-incorporated valinomycin on growth and macromolecular synthesis of normal and ras-transformed 3T3 cells.

    abstract：:Valinomycin is a depsipeptide antibiotic that selectively translocates potassium ion across biologic membranes. This drug has been reported to display antitumor effects, but its use has been limited by its extreme toxicity. However, its incorporation into lipid vesicles (liposomes) has resulted in a reduction in toxic...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00267946

    authors： Daoud SS,Juliano RL

    更新日期：1989-01-01 00:00:00

  • A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.

    abstract：PURPOSE:To determine toxicities, maximally tolerated dose (MTD), pharmacokinetic profile, and potential antitumor activity of MTA, a novel antifolate compound which inhibits the enzymes thymidylate synthase (TS), glycinamide ribonucleotide formyltransferase (GARFT), and dihydrofolate reductase (DHFR). METHODS:Patients...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1007/s002800050992

    authors： Rinaldi DA,Kuhn JG,Burris HA,Dorr FA,Rodriguez G,Eckhardt SG,Jones S,Woodworth JR,Baker S,Langley C,Mascorro D,Abrahams T,Von Hoff DD

    更新日期：1999-01-01 00:00:00